

Attorney's Docket: 742-01110503

Box Patent Application Commissioner for Patents Washington, D.C. 20231

37 CFR 1.8(a)

Mailing label no.:

37 CFR 1.10

Date: Jan. 30, 2002

## NEW PATENT APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of  SUNG WOO YANG
For (title):
ONE TIME SEARCH
1. TYPE OF APPLICATION
This new application is for a(n) (check one applicable item below):  [X] Original  [ ] Design  [ ] Plant
ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED:
[ ] Divisional [ ] Continuation [ ] Continuation-in-part (CIP)
CERTIFICATE OF MAILING
I hereby certify that this paper or fee (along with any paper referred to a being attached or enclosed) is being deposited on the date shown below with

CHUAW,

Application, Commissioner for Patents, Washington, D.C. 20231

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"

2.	TYPE OF	
	[ ]	The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.
	[ ]	This application claims the benefit of the priority date of an earlier filed application (35 USC 119).  This is an application filed pursuant to 37 CFR 1.53, permitting receipt of a filing date upon filing of specification, claims and drawings, if required, with applicant being given a period of one month from the date of notice to file the fee and oath or
	[X]	declaration. In any event, any parts of this application are missing, please treat this as filing under 37 CFR 1.53 as defined just above.
з.	PAPERS I	ENCLOSED WHICH ARE REQUIRED FOR FILING DATE UNDER 37 CFR 1.53(b):
	<u>3</u> 1	Pages of specification Pages of claims Pages of Abstract Sheets of drawing [X] formal [] informal
4.	[ ] I [ ] J [ ] C [ ] I [ ] S r r [ ] Z	ONAL PAPERS ENCLOSED Preliminary Amendment Information Disclosure Statement Form PTO-1449 Citations Declaration of Biological Deposit Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleoside and/or amino acid sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other
5.	DECL.	ARATION OR OATH
		Enclosed executed by (check all applicable boxes) [X] inventor(s).
		[ ] legal representative of inventor(s). 37 CFR 1.42 or 1.43 [ ] joint inventor or person showing a proprietary interest on
		behalf of inventor who refused to sign or cannot be reached.
		[ ] this is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached.
	[ ]	Not Enclosed. [] Application is made by a person authorized under 37 CFR 1.41(c) on behalf of all (he above named inventor(s). The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently.
		[ ] Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).

6.	INVENTORSHIP STATEMENT
The	<pre>inventorship for all the claims in this application are:    [X] The same</pre>
	[ ] will be submitted.

## 7. LANGUAGE

- [X] English
- [ ] non-English
  - [] the attached translation is a verified translation. 37 CFR 1.52(d).

#### 8. ASSIGNMENT

[X] An assignment of the invention to <u>TECHNO MECCA</u>, INC.

[X] is attached.

[ ] will follow.

## CERTIFIED COPY

Certified copy(ies) of application(s)

(Country)	(Appln no.)	(Filed)	
(Country)	(Appln no.)	(Filed)	
(Country)	(Appln no.)	(Filed)	

from which priority is claimed

- [ ] is(are) attached. A separate "ASSIGNMENT COVER LETTER ACCOMPANYING NEW PATENT APPLICATION" is also attached.
- [ ] will follow.

# 10. FEE CALCULATION (37 CFR 1.16)

A. [X] Regular application

CLAIMS AS FILED										
Number filed	Number Extra	Rate	Basic Filing Fee \$740.00							
Total Claims 37 CFR 1.6(C)(_7- 20=_0_)	0	\$18	0							
Indep. Claims 37 CFR 1.16(b) ( <u>1</u> - 3=)	0	\$84	0							
Multi dep claim(s), if any 37 CFR 1.16(d)	0	\$280	0							

-	dep	claim(s),	, if any 3/	CFR I.	.16(d)	0	\$280	
	]	Amendment	cancelling	extra	claims	enclosed.	_	

[ ] Amendment deleting multiple-dependencies enclosed.
[ ] Fee for extra claims is not being paid at this time.

Filing Fee Calculation

740.00
--------

2200

	B. [] Design application (\$320.00-37 CFR 1.16(f)) Filing Fee Calculation	\$
	C. [] Plant application (\$530.00-37 CFR 1.16(g)) Filing Fee Calculation	\$
11.	SMALL ENTITY STATEMENT(S)	
	[X] This is a filing by a small entity under is(are) attached.	37 CFR 1.9 and 1.27
	Filing Fee Calculation (50% of A, B or C above)	\$ 370.00
12.	REQUEST FOR INTERNATIONAL-TYPE SEARCH (37 CFR 1 (complete, if applicable)	
	[] Please prepare an international-type sear application at the time when national example takes place.	
13.	FEE PAYMENT BEING MADE AT THIS TIME	
	[ ] Not Enclosed	
	[ ] No filing fee is to be paid at this surcharge required by 37 CFR 1. 16( subsequently.)	
	[X] Enclosed	
	<pre>[X] basic filing fee [X] recording assignment</pre>	\$ <u>370.00</u> \$ <u>40.00</u>
	or cannot be reached. (\$130.00; 37 CFR 1.47 and 1.17(h))  [] for processing an application with a specification in a non-English language. (\$130.00; 37 CFR 1.52(d)	\$
	and 1.17(k)  [] processing and retention fee	\$
	<pre>(\$120.00; 37 CFR 1.53(d) and 1.21(1)) [ ] fee for international-type search report</pre>	\$\$
	Total fees enclosed	\$ 410.00
14.	METHOD OF PAYMENT OF FEES	
	[X] Check in the amount of \$370.00 (Ck No. 4792) [] Please charge Deposit Account No. 500314 in	

#### 15. AUTHORIZATION TO CHARGE ADDITIONAL FEES

- [X] The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Deposit Account No. 500314.
  - [X] Any additional filing fees required under 37 CFR 1.16, except Rule 53 filings, which will be paid within the time permitted by PTOL 1533.
  - [X] The filing fee and surcharge under 37 CFR 1.16, patent application processing fee under 37 CFR 1.17 and patent issue fees under 37 CFR 1.18 are intended to be paid by our firm as they arise. As no abandonment is intended by any inadvertent nonpayment of fees, the Commissioner is hereby authorized to charge payment of such fees as from time to time come due if not paid prior to due date to our Deposit Account  $\underline{500314}$ .
  - [ ] Assignment Recordial fees.

16.	INSTRUCTIONS	3 0	m_	ATTENDED \$ \$20 (CD) TO
l n	INSTRUCTIONS	AS	11.( )	CVERPAYMENT

[X] credit Account No. 500314

[ ] refund

Reg. No. 39,081

Tel. No.: (949) 251-0111
Fax No.: (949) 251-1588
E-Mail: cchwu@earthlink.net
USPTO CUSTOMER NO. 25864

CHARLES C.H. WU & ASSOCIATES A PROFESSIONAL CORPORATION

Charles C.H. Wu

7700 IRVINE CENTER DRIVE, SUITE 710 IRVINE, CALIFORNIA 92618-3043

[	]	Incorporation	by	reference	of	added	pages

[	]	Plus A	Added	Pages	For	New	Application	Transmittal	Where	Benefit	Of	Prior
		U.S	. Appl	licatio	on(s)	Cla	aimed					

Number of pages added:\_\_\_\_\_.

[ ] Plus Added Pages For Papers Referred To In Item 4 Above

Number of pages added:\_\_\_\_\_.

[ ] Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added:\_\_\_\_\_.

[ ] Statement Where No Further Pages Added

(If no further pages form a part of this Transmittal then end this Transmittal with this page and check the following item)

[X] This transmittal ends with this page.

يهم فالشيط

## CERTIFICATE OF MAILING

I hereby certify that this paper or fee (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to

BOX PATENT APPLICATION COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

- [X] 37 CFR 1.8(a) with sufficient postage as first class mail.
- [ ] 37 CFR 1.10 as "Express Mail Post Office to Addressee" Mailing label no.:

Date: <u>Jan. 31, 2002</u>



CHARLES C.H. WILL & ST. CHARLES C.H. WILL & ST. CHARLES C.H. T. CHARLES C.H. CORPORATION TOO IRVINE CENTER DRIVE, SUITE 710 IRVINE, CALIFORNIA 92618-3043 U.S.A.

Box Patent Application jc868 U.S. PTO Commissioner for Patents 10/080309
Washington, D.C. 20231